- Home
- VOXR vs PRQR Comparison
VOXR vs PRQR Comparison
Compare VOXR & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VOXR
- PRQR
- Stock Information
- Founded
- VOXR 2014
- PRQR 2012
- Country
- VOXR United States
- PRQR Netherlands
- Employees
- VOXR N/A
- PRQR N/A
- Industry
- VOXR Precious Metals
- PRQR Biotechnology: Pharmaceutical Preparations
- Sector
- VOXR Basic Materials
- PRQR Health Care
- Exchange
- VOXR Nasdaq
- PRQR Nasdaq
- Market Cap
- VOXR 168.0M
- PRQR 179.1M
- IPO Year
- VOXR N/A
- PRQR 2014
- Fundamental
- Price
- VOXR $3.18
- PRQR $2.35
- Analyst Decision
- VOXR
- PRQR Strong Buy
- Analyst Count
- VOXR 0
- PRQR 8
- Target Price
- VOXR N/A
- PRQR $8.88
- AVG Volume (30 Days)
- VOXR 826.5K
- PRQR 346.0K
- Earning Date
- VOXR 08-06-2025
- PRQR 08-07-2025
- Dividend Yield
- VOXR 1.54%
- PRQR N/A
- EPS Growth
- VOXR N/A
- PRQR N/A
- EPS
- VOXR N/A
- PRQR N/A
- Revenue
- VOXR $10,845,445.00
- PRQR $21,212,711.00
- Revenue This Year
- VOXR $16.51
- PRQR N/A
- Revenue Next Year
- VOXR $4.60
- PRQR N/A
- P/E Ratio
- VOXR N/A
- PRQR N/A
- Revenue Growth
- VOXR N/A
- PRQR 85.91
- 52 Week Low
- VOXR $2.21
- PRQR $1.07
- 52 Week High
- VOXR $3.79
- PRQR $4.62
- Technical
- Relative Strength Index (RSI)
- VOXR 43.45
- PRQR 71.45
- Support Level
- VOXR $3.04
- PRQR $2.10
- Resistance Level
- VOXR $3.39
- PRQR $2.51
- Average True Range (ATR)
- VOXR 0.16
- PRQR 0.15
- MACD
- VOXR -0.01
- PRQR 0.03
- Stochastic Oscillator
- VOXR 26.53
- PRQR 82.41
About VOXR Vox Royalty Corp.
Vox Royalty Corp is a returns-focused mining royalty company with a portfolio of royalties and streams spanning eight jurisdictions. It has built intellectual property, a technically focused transactional team, and a sourcing network which has allowed Vox to target the highest returns on royalty acquisitions in the mining royalty sector. The company geographically operates Australia, Nigeria, USA, and Brazil.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.